Dr. Sun, Bill Nai-chau
Dr. Sun, Bill Nai-chau
Dr Sun, Bill Nai-chau co-founded Longbio in 2018. He is also a member of the Board at present.
Dr. Sun boasts a distinguished career as a serial entrepreneur, marked by numerous successes. Notably, he co-founded Tanox Inc. in 1986 and led its R&D department. Tanox, a biotech company based in Houston, US, went public on Nasdaq in 2000. In a significant milestone, the company was acquired by Genentech in 2006 for a staggering sum of 919 million USD. During his tenure at Tanox, Dr. Sun served as the main inventor behind the groundbreaking first-generation anti-IgE antibody, Omalizumab (marketed as Xolair®), which emerged as a blockbuster in asthma and allergic diseases. Since its listing over two decades ago, Omalizumab has amassed cumulative sales revenue exceeding 30 billion USD, with annual revenues still surpassing 4 billion USD.
Prior to his involvement with Longbio, Dr. Sun held the position of Founder and President at Xuhua, a drug discovery company in China, starting from 2001. Under his leadership, Xuhua collaborated on several innovative drug projects with listed companies in China, including the successful approval of Benegrastim (marketed as Ryzneuta®) by the US FDA and China NMPA in 2023.
Dr. Sun's early career included research roles at Oak Ridge National Laboratory and the National Cancer Institute. He earned his Ph.D. from Iowa State University.